KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Sep 2025 value amounting to $137.1 million.

  • Rigel Pharmaceuticals' Cash & Current Investments rose 124.41% to $137.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $399.9 million, marking a year-over-year increase of 84.56%. This contributed to the annual value of $77.3 million for FY2024, which is 35.81% up from last year.
  • Rigel Pharmaceuticals' Cash & Current Investments amounted to $137.1 million in Q3 2025, which was up 26.54% from $108.4 million recorded in Q2 2025.
  • Over the past 5 years, Rigel Pharmaceuticals' Cash & Current Investments peaked at $153.4 million during Q2 2021, and registered a low of $39.3 million during Q1 2021.
  • Over the past 3 years, Rigel Pharmaceuticals' median Cash & Current Investments value was $62.4 million (recorded in 2023), while the average stood at $72.9 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Cash & Current Investments tumbled by 58.98% in 2021, and later spiked by 173.27% in 2022.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Cash & Current Investments stood at $125.0 million in 2021, then tumbled by 53.42% to $58.2 million in 2022, then fell by 2.19% to $56.9 million in 2023, then surged by 35.81% to $77.3 million in 2024, then surged by 124.41% to $137.1 million in 2025.
  • Its Cash & Current Investments was $137.1 million in Q3 2025, compared to $108.4 million in Q2 2025 and $77.1 million in Q1 2025.